Rates of adverse and serious adverse events in children with cystic fibrosis

Jessica E. Pittman, Umer Khan, Theresa A. Laguna, Sonya Heltshe, Christopher H. Goss, Don B. Sanders*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cystic fibrosis (CF) is an autosomal recessive disease characterized by chronic sinopulmonary symptoms and chronic gastrointestinal symptoms that begins in infancy. Children with CF are increasingly being included in clinical trials. In order to fully evaluate the impact of new therapies in future clinical trials, an understanding of baseline adverse event (AE) rates in children with CF is needed. To address this, we determined the rates of common AEs in pediatric patients with CF who participated in two clinical trials. Methods: We reviewed AEs for placebo recipients in the AZ0004 study and inhaled tobramycin recipients in the Early Pseudomonas Infection Control (EPIC) clinical trial. AEs were categorized based on Medical Dictionary for Regulatory Activities (MedDRA) coding classifications and pooled into common, batched AE descriptors. AE rates were estimated from negative binomial models according to age groups, severity of lung disease, and season. Results: A total of 433 children had 8,266 total AEs reported, or 18.1 (95% CI 17.0, 19.2) AEs per person per year. Respiratory AEs were the most commonly reported AEs, with a rate of 7.6 events per person-year. The total SAE rate was 0.33 per person per-year. Cough was the most commonly reported respiratory AE, with 61% of subjects reporting at least one episode of cough within 4 months. The rate ratio of any AE was higher in Spring, Fall, and Winter, compared with Summer. Conclusions: AEs occur commonly in pediatric CF clinical trial participants. Season of enrollment could affect AE rates.

Original languageEnglish (US)
Pages (from-to)972-977
Number of pages6
JournalJournal of Cystic Fibrosis
Volume20
Issue number6
DOIs
StatePublished - Nov 2021

Keywords

  • Clinical Trial
  • Cystic Fibrosis
  • Phase III
  • Study Design

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Rates of adverse and serious adverse events in children with cystic fibrosis'. Together they form a unique fingerprint.

Cite this